跳至主要内容
临床试验/NCT03776461
NCT03776461已完成不适用

Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles

Venus Concept2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2019年3月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Venus Concept
入组人数
25
试验地点
2
主要终点
Subject Satisfaction

研究概览

简要总结

Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of facial wrinkles.

详细描述

The study will evaluate 50 treatment sites in subjects requesting treatment of their facial wrinkles. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Evaluator blinded assessment of photographs

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their facial wrinkles.
  • Able to read, understand and voluntarily provide written Informed Consent.
  • Able and willing to comply with the treatment/follow-up schedule and requirements.
  • Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.

排除标准

  • Implantable defibrillators, cardiac pacemakers, and other metal implants
  • Subjects with any implantable metal device in the treatment area
  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
  • Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.
  • Current or history of any kind of cancer, or pre-malignant moles.
  • Severe concurrent conditions, such as cardiac disorders.
  • Pregnancy or intending to become pregnant during the study and nursing.
  • Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.
  • History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to enrollment , or according to Investigator's discretion .
  • Poorly controlled endocrine disorders, such as diabetes.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).
  • Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.
  • Use of isotretinoin (Accutane®) or other retinoids within six months prior to treatment or as per physician's discretion.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one week before and after each treatment session.
  • Any surgical procedure in the treatment area within the last six months or before complete healing.
  • Treating over tattoo or permanent makeup.
  • Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.
  • As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

结局指标

主要结局

Subject Satisfaction

时间窗: 6 Weeks Post Last Treatment (Around Week 14)

Subjects' assessment of satisfaction with the treatment using a 5 point Subject Satisfaction Scale (0=Very Unsatisfied, 4=Very Satisfied) at 6 weeks and 12 weeks post-treatment.

次要结局

  • Subject Scale - 5 Point Scale for Treatment Tolerability With 0 Being Very Intolerable and 4 Very Tolerable.(Post Treatment at the Baseline, 4 Week and 8 Week treatment visits)
  • Subject Scale - Visual Analog Scale for Pain(Post Treatment at the Baseline, 4 Week and 8 Week treatment visits)

研究者

发起方
Venus Concept
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验